Scott Wolchko To Retire as President and CEO after 10 years of Leadership in Pioneering iPSC-derived Cellular Immunotherapies SAN DIEGO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc.
Selecting the right stability partner is crucial for accelerating your product’s journey to market while ensuring its safety and compliance. A partner with expertise in evolving regulatory ...